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Highlights 
 Atractaspis venoms were shown to have potent procoagulant effects 
 Antivenom efficacy was shown to be poor for all available African antivenoms. 
 
 
Abstract 
Atractaspis snake species are enigmatic in their natural history, and venom effects are 
correspondingly poorly described. Bite reports are scarce but bites have been described as 
causing severe hypertension, profound local tissue damage leading to amputation, and 
deaths are on record. Clinical descriptions have largely concentrated upon tissue effects, 
and research efforts have focused upon the blood-pressure affecting sarafotoxins. 
However, coagulation disturbances suggestive of procoagulant functions have been 
reported in some clinical cases, yet this aspect has been uninvestigated. We used a suite of 
assays to investigate the coagulotoxic effects of venoms from six different Atractaspis 
specimens from central Africa. The procoagulant function of factor X activation was 
revealed, as was the pseudo-procoagulant function of direct cleavage of fibrinogen into 
weak clots. The relative neutralization efficacy of South African Antivenom Producer’s 
antivenoms on Atractaspis venoms were boomslang>>>polyvalent>saw-scaled viper. 
While the boomslang antivenom was the most effective on Atractaspis venoms, the ability 
to neutralize the most potent Atractaspis species in this study was up to 4-6 times less 
effective than boomslang antivenom neutralizes boomslang venom. Therefore, while these 
results suggest cross-reactivity of boomslang antivenom with the unexpectedly potent 
coagulotoxic effects of Atractaspis venoms, a considerable amount of this rare antivenom 
may be needed. This report thus reveals potent venom actions upon blood coagulation that 
may lead to severe clinical effects with limited management strategies. 
Keywords: venom; antivenom; coagulopathy; thrombin; fibrinogen; snake.  
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Introduction 
Species in the Atractaspis genus within the Lamprophiidae snake family are nocturnal 
burrowing venomous snakes (Spawls and Branch, 1995). This genus represents the third 
independent evolution of front-fangs within snakes (Fry et al., 2015).  Their fangs erect on 
a horizontal plane rather than on a vertical plane like in viperids, resulting in descriptive 
common names including switchblade snakes and stiletto snakes. Bites are characterized by 
strong, local pain accompanied by swelling and localized tissue necrosis (amputation 
resulting in some survivors), coagulation disturbances including elevated partial 
thromboplastin time and decreased prothrombin index, rapid and severe hypertension, and 
deaths have been recorded (Coppola and Hogan, 1992; Kochva, 1998; Kurnik et al., 1999; 
Lee et al., 1986; Leisewitz et al., 2004; Tilbury and Verster, 2016).  
Despite their evolutionary novelty and documented severe envenomation effects, their 
venom is underinvestigated relative to the intensive efforts on elapid and viperid snake 
venoms. Work to-date has largely focused on the endothelin-type peptides called 
sarafotoxins which are responsible for the dramatic rise in blood pressure observed 
clinically (Abd-Elsalam, 2011; Atkins et al., 1995; Borgheresi et al., 2001; Goyffon, 1994; 
Ismail et al., 2007; Kawanabe and Nauli, 2011; Kolb, 1991; Mahjoub et al., 2015; Malaquin 
et al., 2016; Nakajima et al., 1989; Nayler et al., 1989; Patocka et al., 2004; Takasaki et al., 
1992; Tilbury and Verster, 2016; Warrell et al., 1976). The only other characterized toxin 
type from Atractaspis venom has been a hemorrhagic metalloprotease (Ovadia, 1987). 
Transcriptome sequencing has shown that toxin types present in the venom include peptides 
(three finger, AVIT, beta-defensin, c-type lectin, cystatin, sarafotoxin, waprin), non-
enzymatic proteins (CRiSP, lipocalin, nerve growth factor) and enzymes 
(acetylcholinesterase, kallikrein-type serine protease, metalloprotease, phospholipase A2) 
(Terrat et al., 2013).  
In snake venoms, procoagulant toxin types include metalloproteases (Casewell et al., 
2015; Debono et al., 2017; Rogalski et al., 2017) and mutant forms of the blood factors FXa 
and FVa which are specifically expressed in venom glands (Cipriani et al., 2017; Earl et al., 
2015; Lister et al., 2017; Trabi et al., 2015). Procoagulant functions produce endogenous 
thrombin by Factor V activation (Vaiyapuri et al., 2015), Factor VII activation (Cipriani et 
al., 2017), Factor X activation (Casewell et al., 2015; Vaiyapuri et al., 2015) and 
prothrombin activation (Casewell et al., 2015; Trabi et al., 2015). The endogenous 
thrombin in turn cleaves fibrinogen to form normal, cross-linked, and strong clots. 
Procoagulant functions may be accompanied by synergistic functions such as Factor XIII 
activation by kallikrein-type serine proteases (Vaiyapuri et al., 2015), and plasmin 
inhibition by kunitz peptides (Eng et al., 2015). This aids in prey subjugation through the 
rapid induction of stroke, while in human victims the venom is diluted into a much larger 
blood volume resulting in defibrinogenation, with death due to internal bleeding such as 
cerebral hemorrhage (Debono et al., 2017; Herrera et al., 2012; Jackson et al., 2016).  
Anticoagulant functions in snake venoms occur in two forms: pseudo-procoagulant 
functions in which a part of the clotting cascade is catalyzed to produce unstable, weak 
clots which are readily broken down; and true anticoagulant functions in which clot 
formation is directly impeded. The pseudo-procoagulant action involves the atypical 
cleavage of fibrinogen by apotypic kallikrein-type serine proteases (Vaiyapuri et al., 2015) 
to form poorly cross-linked clots with short half-lives, leading to a net anticoagulant state 
(Fry, 2015; Hutton and Warrell, 1993). In contrast, true anticoagulant kallikrein-type serine 
proteases or metalloproteases cleave fibrinogen in a destructive, non-clotting manner that 
not only directly depletes the amount of fibrinogen available for clot formation, but the 
fibrinogen degradation products may also be bound by thrombin and thus also reduce the 
amount of thrombin available for clot formation (Casewell et al., 2015; Vaiyapuri et al., 
2015).  
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Both pseudo-procoagulant and anticoagulant functions may be accompanied by a 
myriad of synergistic functions including: alpha-2 antiplasmin blockage by kallikrein-type 
serine proteases (Vaiyapuri et al., 2015); antithromboplastic effects to prevent the formation 
of the prothrombinase complex by Group II PLA2 (Sunagar et al., 2015b); Factor V 
denaturation by kallikrein-type serine proteases (Vaiyapuri et al., 2015); inhibition of the 
enzymatic activity of Factor VIIa and the Factor VIIa/tissue factor complex by three finger 
toxins (Utkin et al., 2015); Factor Xa inhibition by kunitz peptides (Eng et al., 2015); 
plasminogen activation by kallikrein-type serine proteases (Vaiyapuri et al., 2015); 
plasminogen activator release from endothelial cells by vascular permeability by kallikrein-
type serine proteases and metalloproteases ((Casewell et al., 2015; Vaiyapuri et al., 2015); 
platelet inhibition through receptor binding by disintegrins (separately and coupled to 
metalloproteases); Group I and Group II PLA2, lectins and three finger toxins (Arlinghaus 
et al., 2015; Casewell et al., 2015; Sunagar et al., 2015a; Sunagar et al., 2015b; Utkin et al., 
2015); protein C activation by kallikrein-type serine proteases (Vaiyapuri et al., 2015); 
thrombin inhibition by kunitz peptides (Eng et al., 2015); and blood vessel wall degradation 
by kallikrein-type serine proteases and metalloproteases (Casewell et al., 2015; Vaiyapuri et 
al., 2015). Both pseudo-procoagulant and anticoagulant functions promote haemorrhagic 
shock, whether in prey or human victims (Boyer et al., 2015).  
Although coagulotoxic effects are suggested by the scarce clinical reports of 
Atractaspis envenomations, no laboratory studies have been undertaken to elucidate these 
effects. This study aims to fill these knowledge gaps by subjecting the venoms to a battery 
of assays to determine the nature and potency of effects upon the clotting cascade. We 
examined the three broad mechanisms of coagulotoxicity: procoagulant functions leading to 
thrombin production; pseudo-procoagulant functions upon fibrinogen with net 
anticoagulant outcomes; or true anticoagulant functions upon fibrinogen.  
 
Materials and Methods  
Venoms examined 
This study examined six Atractaspis specimens from five African countries in order to 
ascertain the nature and potency of coagulotoxic functions and the relative inhibition by 
available antivenoms. Specimen codes, species designation (as concluded by venom 
suppliers) and confirmed geographic origin were as follows: SP01 A. irregularis Congo; 
SP02 A. bibroni Tanzania; SP03 A. atterima Ghana; SP04 A. fallax Kenya; SP05 A. bibroni 
Tanzania; and SP06 A. irregularis Cameroon. 
 
Coagulation analyses and relative antivenom efficacy 
Coagulation analyses and relative antivenom efficacy studies were conducted as 
previously described by us (Debono et al., 2017; Lister et al., 2017; Rogalski et al., 2017). 
Coagulation analyses were performed on a Stago STA-R Max® automated coagulation 
analyser (Stago, Asnières sur Seine, France) using Stago Analyser software v0.00.04 
(Stago, Asnières sur Seine, France). All experiments were conducted in triplicate, with 
plasma and venom being replaced every 15-30 min to minimise enzyme degradation.  
To check the quality of the plasma (Australian Red Cross (research approval #16-
04QLD-10; 44 Musk Street, Kelvin Grove, Queensland 4059), positive and negative 
controls were conducted and compared to pre-established plasma clotting parameters in the 
presence and absence of an activator (49-51 sec (s) and 526-586s respectively). The 
positive control was conducted by performing a standardised activated Partial 
Thromboplastin Time (aPTT) test (Stago Cat#T1203 TriniCLOT APTT HS). In this test, 50 
µl Kaolin (STA C.K.Prest standard kit, Stago Cat#00597), a coagulation activator, was 
added to 50 µl plasma and incubated for 120 sec. Then, 50 µl CaCl2 (0.025 M, Stago 
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Cat#00367) was added, and time until clot formation was measured. As a negative control, 
test conditions in the absence of venom were replicated: 50 µl buffer solution (30 µl 50% 
deionised H2O / 50% glycerol in 270 µl Owren-Koller (OK) buffer) was added to 50 µl 
CaCl2, 50 µl phospholipid and 25 µl OK buffer, and then incubated for 120 s at 37°C. 75 µl 
plasma was then added and clotting time measured. Both controls were run in triplicate 
before commencing any venom analyses.  
In order to determine clotting times effected by the addition of varying venom 
concentrations, venom working stock solution was manually diluted with Owren Koller 
(OK) Buffer (Stago Cat# 00360) as appropriate in order to perform 10-point dilution series 
(µg/ml: 20, 10, 5, 2.5, 1.33, 0.66, 0.4, 0.2, 0.1, and 0.05). 50 µl of CaCl2 with 50 µl 
phospholipid (cephalin prepared from rabbit cerebral tissue from STA C.K Prest standard 
kit, Stago Cat# 00597, solubilised in OK Buffer) were added to 50 µl of the diluted venom. 
An additional 25 µl of OK Buffer was added to the cuvette and incubated for 120 sec at 
37°C before adding 75 µl human plasma (total volume 250 µl /cuvette). Time until clot 
formation was then immediately monitored by the automated analyser.  
In order to test for co-factor dependence of the venoms, the aforementioned 
coagulation analyses were run both with and without CaCl2 and/or phospholipid. The 
experimental protocol was identical, with the exception that 50 µl OK Buffer was added as 
a substitute for the removed co-factor to ensure consistency in final test volumes (250 µl).  
The relative efficacy of polyvalent and monovalent antivenoms were investigated in 
this study. The previously measured whole plasma clotting times for each venom were used 
as a baseline comparison for the effects of three antivenoms: SAVP boomslang antivenom 
Lot M03852, SAVP polyvalent antivenom Lot L01146, and SAVP saw-scaled viper 
antivenom Lot 2147. For antivenom testing, all test conditions replicated that of the 
coagulation analyses, with the exception that 25µl of antivenom working solution (50 µl 
reconstituted antivenom in 950 µl OK buffer) was used in place of 25µl of OK Buffer: 50 
µl venom, 50 µl calcium, 50 µl phospholipid, 25 µl antivenom, 120 s incubation time, 75 µl 
plasma. Time until clot formation was then immediately measured.  
Coagulation times (sec) for each of the venoms and antivenoms were graphed using 
Prism 7.0 software (GraphPad Software Inc, La Jolla, CA, USA) to produce concentration 
response curves. Calculation of EC50 (concentration of venom at which 50% of the effect is 
observed) values for the venom and antivenom concentration curves for each dataset were 
performed using Prism 7.0 software (GraphPad Software Inc, La Jolla, CA, USA). Data are 
expressed as mean ± SD. After EC50s were calculated, the relative antivenom efficacy as 
indicated by x-fold shift in the clotting curve was calculated using the formula:  
x=((abc)/(def))-1  
a= antivenom EC50 x-axis 
b= antivenom EC50 y-axis 
c= antivenom starting clotting time 
d= venom EC50 x-axis 
e= venom EC50 y-axis  
f= venom starting clotting time. 
Values ‘c’ and ‘f’ account for the initial shift in clotting time observed for the highest 
venom concentration (20 µg/mL) when comparing conditions in the presence vs. the 
absence of antivenom. Subtraction of ‘1’ transforms the calculated ratio into a value 
representing the x-fold shift of the clotting curves following antivenom addition. For 
example, if there is no shift of the antivenom curve compared to venom curve (ie. the 
numerator divided by the denominator), then the parenthetical value would equal one, and 
one minus one would result in a zero-shift value for antivenom efficacy. 
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Calibrated Automated Thromography (CAT) 
Calibrated automated thrombography studies were conducted as previously described 
by us (Lister et al., 2017). Thrombin generation was measured by a Calibrated Automated 
Thrombogram (CAT, Stago), using the method previously described by Hemker (Hemker, 
2005; Hemker et al., 2003; Hemker et al., 2002) . The following was pipetted into a 96-well 
round-bottom microtiter plate (Thermo Fisher Scientific, Waltham, Massachusetts, USA):  
a starting volume of 80μL of pre-warmed human plasma (37°C), 10μL of venom, and 10μL 
of phospholipid. The plate was then inserted into a Thermo Fisher Fluoroskan fluorometer 
(Thermo Labsystem, Helsinki, Finland). The default 10-minute incubation step was 
removed so as to capture the initial thrombin formation. Prior to starting, dispensing lines 
were washed and then primed with pre-warmed 2.5 mmol/l fluorogenic substrate in 5 
mmol/l CaCl2 (FluCa-Kit; Diagnostica Stago). The test was then automatically initiated by 
dispensing 20μL of the fluorogenic substrate into each well and run at 37°C for 60-min, 
with readings automatically taken every 20 sec. For each test, venom was added to an 
enzymatic buffer (150mM NaCl & 50mM Tris-HCL, pH 7.4) and manually pipetted into 
the wells for final concentrations of 0.083μg/ml. Tests were performed in triplicate for each 
experiment with three calibrators per half plate. Calibrators adjusted for any internal filter 
effects and eliminated any variation in plasmas. For the calibrator assays, phospholipid and 
a venom trigger was substituted with a thrombin-α2-macroglobulin complex solution of a 
known concentration (thrombin calibrator, Stago, US). For each thrombin generation 
measurement, the following parameters were recorded by the Thrombinoscope software 
(Maastricht, The Netherlands): the endogenous thrombin potential (ETP), represented by 
the activity of free thrombin multiplied by the time it remains active in the plasma (area 
under the curve); maximum concentration of thrombin (peak); and lag-time (time to start). 
The RAW data was then converted by the Thrombinoscope software into thrombin activity 
(nM) corresponding to the calibrator (Hemker, 2005; Hemker et al., 2003; Hemker et al., 
2002). 
 
Zymogen activation: Factor X and Prothrombin 
To determine the relative rate of Factor X activation by the venom samples, the 
following were added into each well using a 384-well plate (black, Lot#1171125, nunc™ 
Thermo Scientific, Rochester, NY, USA) and performed in triplicate per venom: 10 μL of 
0.001µg/µl venom, 10 μL of 0.01µg/µl human Factor X zymogen (Haematologic 
Technologies Inc. HCP-0050), and 10 μL each of CaCl2 (0.025 M, Stago Catalog # 00367) 
and phospholipid (cephalin prepared from rabbit cerebral tissue adapted from STA C.K 
Prest standard kit, Stago Catalog # 00597, solubilised in 5 ml of OK Buffer (STA Owren 
Koller Buffer (Stago Cat# 00360)). Immediately thereafter, 60 μL of quenched fluorescent 
substrate was automatically dispensed per well (total volume of 100 µl in the well; 20 µl /5 
ml OK buffer) using the following substrate: ES011 (Boc-Val-Pro-Arg-AMC. Boc: t-
Butyloxycarbonyl; 7-Amino-4-methylcoumarin) (Lot #: NZY08, www.rndsystems.com). 
The hydrolysis reaction was monitored via fluorescence at 320/405 nm 
(excitation/emission). The amount of fluorescence was measured every 10 sec for a total of 
400 min. The machine was programmed to shake the plate for three sec before each reading 
to maintain homogeneity in the wells, and the plate was warmed in the machine to 37C to 
mimic the human body. Human Factor Xa enzyme (0.01 µg/µl) (7.5 mg/ml HCXA -OO60 - 
R & D systems) was used as positive control to ensure functionality of the substrate. 
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Human Factor X (0.01 µg/µl) was used as a negative control to ensure it did not directly 
cleave the substrate without the presence of venom. 
 
Thromboelastography 
Clot strength assays were conducted using a Thromboelastograph (TEG5000) using 
3.2% citrated human plasma or 4 mg/ml human fibrinogen. 75 μL of 0.025 M CaCl2 to 
reverse citration (Stago catalog# 00367), 75 μL phospholipid from the STA CK Prest 
(Stago catolog# 00597), 35 μL of µl Owren-Koller (OK) buffer (Stago catalog# 00360), 
and 7 μL 1μg/μl crude venom were added before 168 μL plasma or fibrinogen were added 
and the test immediately started. Results were obtained for 30 min. If no clot was formed, 7 
uL of thrombin from the Stago Liquid Fib Kit (Stago catalog# 00673) was added in order to 
perform a Claussian test (Clauss, 1957) 
 
Cleavage of fibrinogen 
Fibrinogen cleavage studies were conducted as previously described by us (Dobson et 
al., 2017; Koludarov et al., 2017). 1 mm 12% SDS-PAGE gels were prepared using the 
following recipe for the resolving gel layer: 3.3 ml deionised H2O, 2.5 ml 1.5 M Tris-HCl 
buffer pH 8.8 (Tris - Sigma-Aldrich, St. Louis, MO, USA; HCl - Univar, Wilnecote, UK), 
100 μL 10% SDS (Sigma-Aldrich, St. Louis, MO, USA), 4 ml 30% acrylamide mix (Bio-
Rad, Hercules, CA, USA), 100 μL 10% APS (Bio-Rad, Hercules, CA, USA), 4 μL TEMED 
(Bio-Rad, Hercules, CA, USA); and stacking gel layer: 1.4 ml deionised H2O, 250 μL 0.5 
M Tris-HCl buffer pH 6.8, 20 μL 10% SDS (Sigma-Aldrich, St. Louis, MO, USA), 330 ml 
30% acrylamide mix (Bio-Rad, Hercules, CA, USA), 20 μL 10% APS (Bio-Rad, Hercules, 
CA, USA), 2 μL TEMED (Bio-Rad, Hercules, CA, USA). 10x gel running buffer was 
prepared using the following recipe: 250 mM Tris (Sigma-Aldrich, St. Louis, MO, USA), 
1.92 M glycine (MP Biomedicals), 1% SDS (Sigma-Aldrich, St. Louis, MO, USA), pH 8.3. 
Human fibrinogen was reconstituted to a concentration of 2 mg/ml in isotonic saline 
solution, flash-frozen in liquid nitrogen and stored at -80 °C until use. Freeze-dried venom 
was reconstituted in deionised H2O and concentrations were measured using a Thermo 
Scientific™ NanoDrop 2000. Assay concentrations were a 1:10 ratio of venom:fibrinogen. 
The following was conducted in triplicate for each venom: Five “secondary” aliquots 
containing 10 μL buffer (5 μL of 4x Laemmli sample buffer (Bio-Rad, Hercules, CA, 
USA), 5 μL deionised H2O, 100 mM DTT (Sigma-Aldrich, St. Louis, MO, USA)) were 
prepared. A “primary” aliquot of fibrinogen (volume/concentration as per the above) was 
warmed to 37 °C in an incubator. 10 μL was removed from the primary aliquot (“0 min 
incubation” fibrinogen control) and added to a secondary aliquot, pipette mixed, and boiled 
at 100C for 4 min. 4 μg (dry weight) of venom was then added to the primary aliquot of 
fibrinogen (amounting to 0.1 mg/ml of venom and 1 mg/ml of fibrinogen in 40 μL total 
volume), pipette mixed, and immediately returned to the incubator. At each incubation time 
period (1 min, 5 mins, 20 mins, and 60 mins), 10 μL was taken from the primary aliquot, 
added to a secondary aliquot, pipette mixed, and boiled at 100C for 4 min. The secondary 
aliquots were then loaded into the gels and run in 1x gel running buffer at room temperature 
for 20 min at 90 V (Mini Protean3 power-pack from Bio-Rad, Hercules, CA, USA) and 
then 120 V until the dye front neared the bottom of the gel. Gels were stained with colloidal 
coomassie brilliant blue G250 (34% methanol (VWR Chemicals, Tingalpa, QLD, 
Australia), 3% orthophosphoric acid (Merck, Darmstadt, Germany), 170 g/L ammonium 
sulfate (Bio-Rad, Hercules, CA, USA), 1 g/L coomassie blue G250 (Bio-Rad, Hercules, 
CA, USA)), and destained in deionised H2O. 
To quantify the band intensities in the gels, scanned gel images were uploaded to 
ImageJ (Version 1.4.3.67, NIH, 2006). Gel images were converted to black and white and 
adjusted for brightness and contrast. Using the rectangular tool control, bands were selected 
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and defined as the first lane. Subsequent bands comprising of venom treatments with 
incubations of 1, 10, 20, 30, 40, 50 and 60 min were defined as lanes 2-8. Selected bands 
were then plotted, and each peak was isolated using the line-drawing function by drawing 
vertical lines down from the center of each trough. Using the wand function, band-intensity 
values were automatically produced by clicking on isolated peaks. These values were then 
exported to Excel, where the degradation of fibrinogen chains was calculated as proportions 
of the control.  
 
Cleavage of fluorescent substrates 
Fluorescent substrate cleavage studies were conducted as previously described by us 
(Cipriani et al., 2017; Debono et al., 2017; Dobson et al., 2017; Koludarov et al., 2017). A 
working stock solution of freeze-dried venom was reconstituted in a buffer containing 50% 
deionised H2O/50% glycerol (>99.9%, Sigma) at a 1:1 ratio to preserve enzymatic activity 
and reduce enzyme degradation with the final venom concentration of 0.1 mg/ml, and then 
stored at -20°C. For assessing the PLA2 activity a fluorescence substrate assay (EnzChek® 
Phospholipase A2 Assay Kit, ThermoFisher Scientific). A working stock solution of freeze 
dried venom was reconstituted in a buffer containing 50% deionised H2O/50% glycerol 
(99.9%, Sigma) at a 1:1 ratio to preserve enzymatic activity and reduce enzyme degradation 
with the final venom concentration of 0.1 mg/ml, and then stored at -20°C. Venom solution 
(0.1 µg in dry venom weight) was brought up to 12.5 µl in PLA2 reaction buffer (250 mM 
Tris-HCL, 500 mM NaCl, 5 mM CaCl2, pH 8.9) and plated out in triplicates on a 384 well 
plate. Triplicates were measured by adding 12.5 µl quenched 1 mM EnzChek® 
Phospholipase A2 substrate per well (total volume 25 µl/well) over 100 cycles at an 
excitation of 485 nm and emission of 520 nm, using a Fluoroskan Ascent (ThermoFisher 
Scientific). The negative control consisted of PLA2 reaction buffer and substrate only.  
For testing on RDES substrates (Fluorogenic Peptide Substrate, R & D systems Cat#s 
ES001, ES002, ES005 AND ES0011, Minneapolis, Minnesota), 10ul of 0.01 µg/µl venom 
stock was plated in triplicate on a 384-well black plate and measured by adding 90 µl 
quenched fluorescent substrate per well. The substrate concentration was 10 µl of each 
substrate stock solution dissolved into 4.990 ml of enzyme buffer (150 mM NaCl and 50 
mM Tri-HCl pH 7.4). Fluorescence was monitored over 400 min or until activity ceased. 
Excitation was at 320 nm and emission was at 405 nm for substrates ES001, ES002 and 
ES005. Excitation was at 390 nm and emission was at 460 nm for substrate ES011. The 
machine was programmed to shake the plate for three sec before each reading to maintain 
homogeneity in the wells. 
 
Statistical analyses:  
All variables were measured in triplicate for each sample and the mean values for each 
sample were used to test for Pearson's correlations between antivenom efficacy, clotting 
time, CAT, TEG, factor X activation, activity on Substrate 2, and cleavage of each 
fibrinogen chain. We note that some may argue for a non-parameteric equivalent such as 
Spearman's rank correlation due to the small sample sizes (N=6 for all correlations except 
for antivenom vs clotting time which is N=4), but variables passed a Shapiro-Wilks test of 
normality (unsurprisingly due to the small samples and low power of this test) and, more 
importantly, we were interested in the actual values of the variables rather than their ranks. 
Nevertheless, we note that Spearman's rank correlations give qualitatively similar or 
identical results to the Pearson's correlations we report herein. 
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Results 
Coagulation analyses and relative antivenom efficacy  
To evaluate pro- or anticoagulation activities, assessment was carried out on an 
automated viscosity-based (mechanical) detection system analyzer (Stago STA-R Max) that 
measures clotting times with a maximum reading time of 999 sec – the analyzer’s limit. 
There was significant variation between samples in the ability to clot plasma, with times to 
clot (in sec) at the maximum venom concentration tested (20 µg/ml) being: SP01 (19.1+/-
0.20 sec), SP02 (100+/-4.76 sec), SP03 (537.13+/-16.06 sec), SP04 (50.03+/-1.59 sec), 
SP05 (23.77+/-0.49 sec), and SP06 (379.50+/-16.96 sec) (Figure 1). Only SP03 did not 
significantly differ relative to the spontaneous clotting time of this batch of recalcified 
plasma (556.33+/-29.92 sec). The actions were shown to be calcium-dependent, with the 
complete abolition of activity in the absence of calcium. The relative presence of 
phospholipid was also a driving factor but to a much less extent, with the venoms clotting 
slower in the absence of phospholipid by a ratio of: 1.9 (SP01), 1.7 (SP02), 1.7 (SP04), and 
1.8 (SP05). 
In addition to clotting ability varying significantly between the specimens, antivenom 
efficacy also varied moderately between samples (Figure 1). Testing on SP01 revealed that 
the boomslang antivenom (8.55+/-1.2 times shift in clotting curve) was much more 
effective than the polyvalent (3.2+/-0.09 times shift in clotting curve) or saw-scaled viper 
(1.84+/-0.01 times shift in clotting curve). Therefore, for the other species boomslang 
antivenom was tested, with relative clotting curve shifts of: SP02 (21.78+/-0.89 times shift 
in clotting curve); SP04 (21.98+/-0.45 times shift in clotting curve); and SP05 (12.03+/-
0.12 times shift in clotting curve). These values are independent of relative venom potency, 
as they reflect the proportional shift of a clotting curve by the antivenom. While there was 
not a significant statistical correlation between clotting time and antivenom efficacy 
(r=0.820, t=2.024, df=2, P=0.180), the sample size was N=4, which limited our ability to 
conclusively demonstrate this effect, despite the high estimated correlation coefficient 
(r=0.82). Thus, that the boomslang antivenom was able to proportionally shift the clotting 
curve more for the two more moderately potent venoms (SP02 and SP04) than to the two 
more potent venoms (SP01 and SP05) is therefore suggestive that the differences in surface 
chemistry driving clotting activity are key sites that also guide relative antivenom efficacy.  
 
Calibrated Automated Thromography (CAT)  
To evaluate the ability to generate endogenous thrombin in plasma samples, 
assessment was carried out on a Fluoroskan Ascent fluorometer with the CAT (calibrated 
automated thrombography) function. The venoms showed significant diversity in the ability 
to produce thrombin (Figure 2), with SP01 and SP05 being the most potent. We found a 
very strong correlation between CAT and clotting time (r=0.912, t=4.444, df=4, P=0.011).  
 
Zymogen activation: Factor X and Prothrombin  
To evaluate the ability to activate the zymogens Factor X and prothrombin, assessment 
was carried out on a Fluoroskan Ascent fluorometer. Zymogen testing revealed that the 
clotting action (Figure 1) and thrombin production (Figure 2) was not due to activation of 
prothrombin but was due to the activation of Factor X (Figure 3). Consistent with the 
clotting times and CAT patterns, the most potent were SP01, SP04 and SP05. While we 
were unable to demonstrate a direct correlation between Factor X activation and CAT (r=-
0.694, t=-1.931, df=4, P=0.126) or Factor X activation and CAT (r=-0.551, t=-1.320, df=4, 
P=0.258), this may be a result of low sample size given the reasonably high estimated 
correlation coefficient. The correlation coefficient is a negative value because a higher level 
of Factor X activity would produce quick CAT and clotting times. This discordance 
between correlation coefficient and other statistical values would have been strongly 
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influenced in the Factor X activation assay by SP05 being disproportionately more potent 
than SP01 and SP04, in contrast to the clotting and thrombin generation assays where SP01 
and SP05 did not vary significantly (Figures 1 and 2). This variance in relative patterns may 
be explained by the clotting and thrombin assays being run in plasma and thus additional 
interactions and dynamics coming into play beyond that of simple Factor X activation as 
assayed in this test.  
 
Thromboelastography 
To evaluate the strength of plasma clots formed by procoagulant mechanisms, 
assessment was undertaken using a Thromboelastograph (TEG) viscoelastic hemostatic 
assay, where strength of the clot is measured as the maximum amplitude of a clotting curve 
(i.e. thrombus velocity curve) in millimeters. TEG analyses of venom effects upon plasma 
showed that all venoms were able to form strong, stable clots (Figure 4A) consistent with 
their relative plasma clotting times (Figure 1), CAT effects (Figure 2) and in line with the 
ability to activate Factor X (Figure 3). Relative to the time to spontaneous clotting 
exhibited by recalcified plasma, the venoms were faster by ratios of: SP01 (21.80), SP02 
(3.02), SP03 (1.11), SP04 (8.23), SP05 (12.67), AND SP06 (1.56). Only SP03 did not differ 
significantly from the control, which was also consistent with the negligible effects upon 
clotting time (Figure 1), CAT (Figure 2) and Factor X activation (Figure 3) results. TEG 
plasma testing was strongly and positively correlated with both clotting time (r=0.983, 
t=10.696, df=4, P=0.0004) and CAT (r=0.835, t=3.040, df=4, P=0.038), but in contrast we 
found no evidence of a correlation between TEG and Factor X activation (r=-0.486, t=-
1.028, df=4, P=0.362) due to the disproportionate effect SP05 had in the Factor X 
activation assay. 
Thromboelastography analyses of direct effects upon fibrinogen showed that only 
SP01 and SP05 were also able to cleave fibrinogen to form clots of about 50% the strength 
of those formed by thrombin (Figure 4B). None of the other venoms were able to clot or 
degrade fibrinogen in such a way that thrombin added after 30 min formed other than a 
normal size and strength clot (Figure 4C).  
 
Cleavage of fibrinogen 
To quantify the cleavage of the fibrinogen chains (Aα, Bβ and γ), 1D reduced PAGE 
gels were performed for fibrinogen samples which had been incubated with venom. 
Extreme diversity between the specimens was evident in the relative speed of cleavage of 
Aα and Bβ chain cleavage (Figure 5), with SP05 being the most potent in this regard, but 
with none of the venoms cleaving the gamma chain. Normalised potency values for the Aα 
chain cleavage activity were SP01 (0.90+/-0.2), SP02 (0.171+/-0.12), SP03 (0.197+/-0.03), 
SP04 (0.54+/-0.02), SP05 (0.99+/00.01), and SP06 (0.55+/-0.01) while normalised potency 
values for the Bβ chain cleavage activity were SP01 (0.32+/-0.07), SP02 (0.14+/-0.09), 
SP03 (0.08+/-0.02), SP04 (0.15+/-0.02), SP05 (0.98+/-0.02), and SP06 (0.39+/-0.03). 
Activity on substrate ES002 was strongly positively correlated with the ability to degrade 
both the Aα (r=0.829, t=2.968, df=4, P=0.041) and Bβ (r=0.807, t=2.731, df=4, P=0.052) 
chains of fibrinogen. Note that the correlation is significant for the alpha chain and 
marginally non-significant in the beta chain, though the latter is likely a consequence of the 
small sample size as the correlation coefficient is strong (r>0.7). The ability to degrade the 
alpha and beta chains of fibrinogen was also strongly positively correlated with each other 
(r=0.786, t=2.544, df=4, P=0.064). 
 
Cleavage of fluorescent substrates 
To assess enzymatic activities, a Fluoroskan Ascent fluorometer and fluorescent 
substrates known to be cleaved by metalloprotease, serine protease and phospholipase A2 
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enzymes were used as proxy indicators for the presence of certain toxin classes. There was 
a tremendous functional diversity within the venoms (Figure 6). There was no taxonomical 
pattern between the species according to enzymatic activity in relation to species 
designation or confirmed geographical origins.  
Discussion  
The Atractaspis venoms displayed the ability to clot plasma (Figure 1) due to thrombin 
generation (Figure 2) as a result of Factor X activation (Figure 3), resulting in the formation 
of strong clots in plasma (Figure 4). The cofactor dependency was absolute in regards to 
calcium, with all venoms displaying no activity in the absence of calcium, while tests 
performed in the absence of phospholipid displayed almost half the activity. While SP01 
and SP05 were also shown to directly clot fibrinogen (Figure 4B), the speed of action was 
much slower than that of the thrombin-generation driven clotting and thus would not be 
likely to contribute to envenomation effects. The other species neither directly clotted 
fibrinogen (Figure 4B) nor degraded it to such an extent that thrombin was not able to form 
a strong, stable clot from the venom-treated fibrinogen (Figure 4C). Consistent with this, 
SP01 and SP05 were most potent in the fibrinogen gel analyses (Figure 5). 
The relative potency of SP01 and SP05 were on par with that of snakes characterized 
as having lethal levels of thrombin-generation ability such as saw-scaled vipers (Echis 
species) (Rogalski et al., 2017). In addition to risk from bites in the wild, specimens from 
the Atractaspis genus are regularly imported into the exotic pet trade and thus are a source 
of exotic snakebite in the developed world. Therefore, the potent procoagulant action 
revealed in this study is cause for concern.  
In this study, the ability of available African antivenoms to neutralise the venoms 
varied, with the SAVP boomslang antivenom being the most relatively effective. While the 
level of efficacy of the best neutralized species was less than half that of the target species 
Dispholidus typus (Debono et al., 2017), the most potent species were neutralized at a 
relative level of less than seven times that of D. typus efficacy levels and on par with the 
poorly neutralized Thelatornis mossambicus (Debono et al., 2017). This suggests that, 
while the SAVP boomslang antivenom does neutralize the coagulotoxic effects of 
Atractaspis venoms, the efficacy levels indicate that impractical, large amounts of 
antivenom would be required. In contrast, as the SAVP polyvalent and saw-scaled 
antivenoms performed comparatively poorly, even under the idealized testing regime in this 
study, it is very unlikely they would have any significant clinical efficacy.  
The protocols used in this study to characterize coagulation effects, cofactor 
dependency and antivenom efficacy have been previously validated on diverse genera 
ranging from colubrids (Dispholidus and Thelatornis) (Debono et al., 2017), elapids 
(Hoplocephalus, Notechis, Paroplocephalus and Tropidechis) (Lister et al., 2017) and 
viperids (Echis) (Rogalski et al., 2017). These protocols have been shown to be more 
precise in characterizing the potency and specificity of the coagulation functions than 
historical WHO protocols incorporating the MCD (minimum coagulant dose) method 
(Theakston and Reid, 1983).  
Similarly, the antivenom testing protocol utilized in this study provides a more accurate 
estimation of antivenom neutralization ability than the previous WHO methods. Our new 
method prioritizes rapid, high-affinity antibody-toxin interactions more reflective of real-
world scenarios (Debono et al., 2017; Lister et al., 2017; Rogalski et al., 2017). In contrast, 
the traditional WHO protocol uses prolonged incubation times and thus may overestimate 
efficacy (Segura et al., 2010; WHO, 1981, 2010a, b), particularly for coagulotoxic venoms 
which readily degrade. This was shown by us in our study of Echis venoms which showed 
a much narrower taxonomic spectrum of efficacy for the ICP EchiTab-Plus-ICP antivenom 
(Rogalski et al., 2017) than that which it had been attributed to through the use of the WHO 
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prolonged-incubation protocol (Segura et al., 2010). Indeed, Vargas et al. (2011) observed 
significant loss of coagulant ability in Oxyuranus venoms incubated for 30 min compared 
to 3 min. 
Thromboelastography in this study was able to discriminate between procoagulant 
(Figure 4A) and pseudo-procoagulant (Figure 4B) effects. This method, and the 
thromboelastometry modification, are becoming increasingly important in snake venom 
research for such studies due to the ability to determine clot strength and accurately 
quantify specific effects upon clotting (Dambisya et al., 1994, 1995; Hiremath et al., 2016; 
Jackson et al., 2016; Nagel et al., 2014; Nielsen, 2018; Nielsen and Bazzell, 2017; Nielsen 
and Boyer, 2016; Nielsen et al., 2017a; Nielsen et al., 2016, 2017b; Nielsen et al., 2018; 
Oguiura et al., 2014; Strydom et al., 2016).  
Calibrated automated thrombography has also been shown to be useful in determining 
the ability of venoms to generate thrombin (Isbister et al., 2010; Lister et al., 2017). In this 
study, the venoms were shown to have similar activity levels (i.e. areas under the curve) but 
with different initiation times and slopes to peak formation (Figure 2). The nature of the 
enzymatic actions responsible for these differences should be the subject of future work.   
While it was beyond the scope of this study to determine the specific toxin type 
responsible for the Factor X activation, the cross-reactivity of the Atractaspis venoms with 
SAVP boomslang antivenom suggests that metalloprotease toxins are the responsible 
agents due to the well-characterized nature of boomslang venom as dominated by 
coagulotoxic P-III type snake venom metalloproteases (SVMP) (Debono et al., 2017; 
Kamiguti et al., 2000; Pla et al., 2017). Factor X activating SVMP have been previously 
only ever characterized from Bothrops, Daboia, Echis and Macrovipera viperid venoms 
(Casewell et al., 2015; Hofmann and Bon, 1987; Kisiel et al., 1976; Siigur et al., 2004; 
Takeya et al., 1992). All Factor X activating SVMP are coupled to a pair of lectin chains 
(thus are P-IIId SVMP) and are calcium dependent (Morita, 1998). Factor X activation has 
also been reported for calcium-dependent kallikrein-type serine proteases from Bungarus 
and Ophiophagus elapid venoms and Cerastes viperid venoms (Morita, 1998; Vaiyapuri et 
al., 2015). However, the relative levels or potency of the Factor X activating kallikrein-type 
serine proteases in Bungarus, Ophiophagus and Cerastes venoms suggests that they play 
little, if any, role in prey capture or the development of clinical pathologies in those 
venoms.  
The ability to cleave fibrinogen in a thrombin-like, pseudo-procoagulant manner to 
form weak, unstable clots (Figure 4B) has only been previously reported in viperid venoms 
and in those venoms have been shown to be due to kallikrein-type serine proteases 
(Vaiyapuri et al., 2015). In contrast, the ability to degrade fibrinogen in a non-clotting 
manner (Figure 5) has been widely observed for SVMP in snakes (Casewell et al., 2015) 
and for kallikrein-type serine proteases in lizard and snake venoms (Hendon and Tu, 1981; 
Koludarov et al., 2017; Vaiyapuri et al., 2015).  
While fibrinogen clotting cleavage has been reported for only kallikrein-type serine 
proteases, it remains to be elucidated in Atractaspis venoms which toxin type is responsible 
for this function. This should be the subject of future work, just as such efforts should be 
undertaken to confirm SVMPs are responsible for the Factor X activation activity in these 
enigmatic and rare venoms. In addition, DNA typing of specimens should be undertaken in 
order to conclusively link taxonomy with toxinology in these species which are notoriously 
hard to identify using only external features such as scalation patterns. 
In conclusion, this study reveals previously unknown and extreme potent coagulotoxic 
actions in the Atractaspis genus and thus provides information to guide clinicians. 
Importantly, our results suggest limited management options in treating Atractaspis 
envenomations due to poor antivenom neutralization capacity.  
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Figures 
 
Figure 1: Clotting times, coagulation dose-response curve and normalised logarithmic 
transformed views for effects upon recalcified plasma. Red curve lines represent venom in 
optimal conditions (i.e. with calcium and phospholipid) while other curve colours represent 
the clotting activity remaining after 2 minute preincubation of venom with an antivenom 
and then the same dilution series were run as for the red line protocol. The antivenom 
remained a constant in the second protocol while the venom was diluted against it as per the 
curve graph x-axis concentrations (µg/ml). The curve graph y-axis is time (sec). 
Normalised logarithmic graph x-axis is log concentration (µg/ml) and y-axis is normalized 
time (%). Values are means from N=3. Standard deviation bars are shown for each data 
point, although for most points the error bars are smaller than the dot point. 
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Figure 2: Calibrated Automated Thrombogram curves for 0.083 µg/ml venom 
concentration on human plasma. X-axis is time (sec) and y-axis is nM of thrombin 
production. Values are N=3. 
 
Figure 3: Relative ability to activate Factor X. Values are N=3. 
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Figure 4: Overlaid thromboelastography traces showing effects of: A) ability to clot 
recalcified plasma relative to spontaneous clotting control; B) samples ability to clot 
fibrinogen relative to thrombin control; and C) thrombin added to samples which did not 
clot fibrinogen after 30 min in order to test for venom-induced fibrinogen degradation 
relative to blank contol. R = time to initial clot formation. MA (maximum amplitude) = clot 
strength. Values are N=3 means and standard deviation. 
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Figure 5: Differential ability to degrade the alpha, beta and gamma chains of fibrinogen. 
Experiments were conducted in triplicate. A) Representative 1D-SDS PAGE gel images 
showing the differential cleavage of fibrinogen over the time periods 1, 5, 20 and 60 min. 
B) Fibrinogen cleavage visualized as graphing of the change in band density over time. 
Values are N=3. 
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Figure 6: Relative venom (10 ng/μL) action upon fluorogenic peptide substrates: ES001 
(Mca-PLGL-Dpa-AR-NH2); ES002 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-
Lys(Dnp)-NH2); ES005 (Mca-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH); ES011 
(Boc-Val-Pro-Arg-AMC. Boc: t-Butyloxycarbonyl; 7-Amino-4-methylcoumarin); and 
E10217 (glycerophospho-ethanolamine with a BODIPY® FL dye-labeled sn-2 acyl chain). 
Broad enzyme classes known to cleave a particular substrate are shown parenthetically: 
PLA2 = phospholipase A2; MP = metalloprotease; and SP = serine protease. Column values 
obtained from normalisation of slope values. X axis: species name; Y axis: absorbance 
percentage. Analysis of triplicates was conducted on GraphPad PRISM 7.0 and error bars 
indicate standard deviation. 
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